BioSpace News Archive

Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from National Medical Products Administration (NMPA) for its human immunodeficiency virus (HIV) protease inhibitor ASC09F (ASC09/Ritonavir Fixed-Dose Combination). ASC09 has an unprecedented high genetic barrier to resistance and

Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Carsten Boess to its board of directors. Mr. Boess, who has nearly thirty years of industry experience as a finance executive and board member, brings a wealth of experien

Dutch Regulatory Board Supportive of CHOICES Program, Which May Lead Toward Market Authorization for Treatment of People Living with CF

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial have been accepted for presentation in the late-breaking abstract sessions at the Heart Rhythm Society (HRS) Scientific Sessions. The abstract will be presented as a webinar on Heart Rhythm 365, the society’s digital informati

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that data from its Head-to-Head Burn trial was published in the Journal of Burn Care & Research . This abstract was accepted for a podium presentation at the American Burn Association Meeting, which was cancelled due to the COVID-19 pandemic. Eight patients with deep-p

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced its response to the COVID-19 pandemic and related impact on Ocular Therapeutix’s business operations. “In the midst of the global COVID-19 pandemic, our first priority is for the safety and well-being of ou

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced receipt of the CE (Conformité Européenne) mark for its first-in-class would care product, AC5 TM Topical Hemostat (“AC5”). The CE mark provides authorization to commercialize AC5 in Europe as a dressing and to control bleeding in skin wounds in both out- and in-patient settings. Chi

Tabula Rasa HealthCare Corporation ® (NASDAQ: TRHC) , a healthcare technology company advancing the field of medication safety, announced today a partnership with Irvine-based HealthQuest Esoterics , Inc. to support the preparation and delivery of thousands of testing kits for the detection of SARS-CoV-2, the virus that causes Coronavirus Disease 2019 (COVID-19). The testing kits will be available for TRHC’s PrescribeWellness nationwi

Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has completed a $20 million private placement with Morningside Venture (I) Investments Limited (“Mor

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZA™ (angiotensin II) for an emergency medical program in patients with septic shock due to COVID-19 at the Centre Hospitalier Interrégional Edith Cavell (CHIREC) Delta Hospital in Brussels, Belgiu